每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 每经AI快讯，艾德生物1月5日晚间发布公告称，截至2025年12月31日，公司通过回购专用证券账户以 集中竞价交易方式实施回购股份约41万股，占公司目前总股本的0.1%，回购股份的最高成交价为21.97 元/股，最低成交价为20.5元/股，支付的总金额约为861万元。 （记者 曾健辉） ...

从资金流向上来看，当日生物制品板块主力资金净流入1.91亿元，游资资金净流出2.73亿元，散户资金净 流入8203.94万元。生物制品板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入(元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 002773 康弘药业 | | 1.18 Z | 18.31% | -3021.77万 | -4.70% | -8748.13万 | -13.61% | | 000661 | 长春高新 | 7444.34万 | 9.43% | -4755.38万 | -6.02% | -2688.95万 | -3.40% | | 688331 荣昌生物 | | 6982.31万 | 10.14% | -2366.87万 | -3.44% | -4615.43万 | -6.71% | | 300122 智飞生物 | | 3724.35万 | 9.83% | 85.58万 | 0.23% | -3809.93万 | -10.05% ...

Core Viewpoint - Wante Bio's stock price has shown a slight increase of 2.00% recently, but the company has experienced a significant decline in revenue and profit year-on-year, indicating potential challenges ahead [1][2]. Group 1: Stock Performance - As of January 5, Wante Bio's stock price reached 45.84 CNY per share, with a market capitalization of 57.96 billion CNY [1]. - The stock has seen a 2.00% increase year-to-date, but has declined by 2.11% over the last five trading days, 1.46% over the last twenty days, and 21.12% over the last sixty days [1]. Group 2: Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion CNY, a decrease of 23.09% year-on-year [2]. - The company recorded a net profit of -173 million CNY, representing a significant decline of 165.04% compared to the previous year [2]. Group 3: Shareholder Information - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 8.60% to 30,124 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which reduced its holdings by 9.8553 million shares, and new shareholder招商国证生物医药指数A, holding 4.9609 million shares [3].

证券代码：600161 证券简称：天坛生物 公告编号：2025-058 北京天坛生物制品股份有限公司 董事离任公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司（以下简称"公司"）董事会于近日收到公司董事张洁明先生递交的书面 辞职报告。现将有关情况公告如下： 一、提前离任的基本情况 ■ 二、离任对公司的影响 根据《中华人民共和国公司法》和《公司章程》等相关规定，张洁明先生的辞职报告自送达公司董事会 之日起生效，张洁明先生的辞职未导致公司董事会成员低于法定人数，不会影响公司董事会正常运作和 公司正常经营。截至本公告披露日，张洁明先生未持有公司股份，不存在应当履行而未履行的公开承诺 事项。公司及董事会对张洁明先生任职期间为公司发展做出的贡献表示衷心感谢！ 公司已于2025年12月31日召开第九届董事会第二十八次会议，审议通过《关于增补董事的议案》，同意 提名梁红军先生为公司第九届董事会董事，任期至第九届董事会换届。本事项尚需提交将于2026年1月 16日召开的公司2026年第一次临时股东会审议。详见 ...

Group 1 - The company has established a fair and reasonable pricing policy for its related party transactions, adhering to legal regulations and internal management systems [2] - The related party transactions are executed based on principles of fairness, justice, and equity, ensuring no harm to the company or its shareholders [3] - Previous related party transactions have been executed smoothly without any defaults, indicating the capability of the involved parties to fulfill their obligations [1] Group 2 - The company will hold its first extraordinary general meeting of shareholders in 2026 on January 16, with both on-site and online voting options available [6][7] - The meeting will take place at a specified location in Beijing, and shareholders must register in advance to attend [14] - Specific voting procedures are outlined for shareholders, including the use of the Shanghai Stock Exchange's online voting system [8][9]

登录新浪财经APP 搜索【信披】查看更多考评等级 根据中国证监会《证券发行上市保荐业务管理办法》、《上海证券交易所上市公司自律监管指引第11号 ——持续督导》等有关法律法规的要求，申万宏源证券承销保荐有限责任公司（以下简称"申万宏源承 销保荐"或"保荐人"）作为润本生物技术股份有限公司（以下简称"润本股份"或"公司"）首次公开发行 股票并上市及持续督导的保荐人，于2025年12月26日至12月29日对润本股份2025年度有关情况进行了现 场检查。 一、本次现场检查的基本情况 申万宏源承销保荐针对润本股份实际情况制订了2025年度现场检查工作计划。为顺利实施本次现场工 作，提高现场工作效率，切实履行持续督导工作，保荐人以邮件方式将现场检查事宜通知润本股份，并 要求公司提前准备现场检查工作所需的相关文件和资料。2025年12月26日至12月29日，申万宏源承销保 荐保荐代表人根据事先制订的现场检查工作计划，采取与公司董事、高级管理人员及有关人员进行沟通 和询问、查看公司生产经营场所、查阅公司原始凭证及其他相关资料等形式，对包括公司治理和内部控 制情况、三会运作情况、信息披露情况、独立性以及与控股股东、实际控制人及 ...

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights that various segments within the pharmaceutical industry have seen multiple stocks with over 100% gains in 2025, particularly in the chemical preparation sector, which has outperformed due to the rise in valuations of innovative drugs and strong clinical data from pipelines [4][13] - The report anticipates continued opportunities in the innovative drug sector, driven by the global competitiveness of Chinese pharmaceutical companies and the recognition of their R&D capabilities by multinational corporations [5][14] - Emerging industries such as AI, brain-computer interfaces, and biomanufacturing are expected to gradually transform various segments of the pharmaceutical field, with ongoing efforts to identify investment opportunities within these areas [5][14] Summary by Sections 1. Performance of Pharmaceutical Segments - In 2025, the chemical preparation sector showed the best performance, with top stocks like Shuyou Shen, Guangsheng Tang, and Anglikang achieving over 100% gains due to favorable clinical data and valuation increases [4][13] - The bioproducts sector, including companies like Sanofi and Rongchang Biopharma, also saw significant gains driven by quality pipelines and business development opportunities abroad [4][13] - The pharmaceutical R&D outsourcing sector experienced a "Davis Double" effect, with companies like WuXi AppTec and Haoyuan Pharmaceutical reporting exceptional performance due to increased demand and exceeding expectations [4][13] 2. Market Trends and Weekly Performance - In the fifth week of December 2025, the pharmaceutical sector declined by 2.06%, underperforming the CSI 300 index by 1.47 percentage points, ranking 28th among 31 sub-industries [6][18] - The hospital sector had the smallest decline at 0.85%, while the offline pharmacy sector faced the largest drop at 4.11% [6][22] 3. Recommendations and Focus Areas - The report continues to recommend investment in the innovative drug sector and its supply chain, particularly in CXO and R&D services, as well as in emerging industries like AI and biomanufacturing [5][7][14] - Monthly and weekly stock recommendations include WuXi AppTec, Sanofi, and Haoyuan Pharmaceutical, among others, indicating a focus on companies with strong growth potential [7][15]

截至2025年12月26日收盘，奥浦迈（688293）报收于52.32元，较上周的52.66元下跌0.65%。本周，奥 浦迈12月22日盘中最高价报53.2元。12月25日盘中最低价报51.2元。奥浦迈当前最新总市值55.77亿元， 在生物制品板块市值排名40/51，在两市A股市值排名3086/5181。 本周关注点 公司公告汇总 公司拟向PharmaLegacy Hong Kong Limited等31名股东发行约14,500,000股股份用于购买资产，并在12个 月内分期发行不超过7,249,516股股份。同时，计划向不超过35名特定投资者发行股份募集配套资金不超 过362,049,857元，导致总股本将相应增加。 业绩披露要点机构调研要点 公司于2026年1月1日发布报告书修订说明，更新了本次交易已履行的决策程序及上市公司注册资本信 息，删除原有关于募集配套资金需经上交所审核和证监会注册的表述，因已取得证监会同意注册批复。 交易信息汇总 奥浦迈拟以发行股份及支付现金方式收购澎立生物医药技术（上海）股份有限公司100.00%股权，交易 价格为145,050.07万元，其中股份支付74,048.70万元，现 ...

Core Viewpoint - The article discusses the performance of stocks categorized as "猛兽股" (beast stocks), focusing on those with a price increase of over 4 times within a year, and highlights the emergence of two distinct trading patterns: the traditional trend model and the volume accumulation model [1][2]. Group 1: Stock Selection Criteria - The selection formula for identifying beast stocks is based on a specific calculation involving the highest high and lowest low over a defined period [1]. - A total of 99 stocks were identified in the market, with 40 stocks filtered through an earnings pre-selection pool, although the specific list is not provided [2]. Group 2: Market Trends and Patterns - The current bull market has seen a significant increase in the volume accumulation model, with a ratio of approximately 6:4 compared to the traditional model [2]. - The volume accumulation model results in steeper price increase slopes and shorter time frames for achieving similar gains, with some stocks completing significant price movements in just days or weeks [2]. - The rise of quantitative trading is closely linked to the volume accumulation model, which emphasizes high-frequency trading and rapid turnover, previously dominated by speculative funds [2]. Group 3: Differences Between Trading Models - The traditional trend model is closely tied to earnings growth, while the volume accumulation model shows little correlation with earnings performance [2][5]. - Stocks selected under the traditional model are fundamentally different from those in the volume accumulation model, reflecting divergent views on the importance of fundamentals versus short-term market sentiment [4][5]. Group 4: Commonalities and Market Implications - Both trading models exhibit a common principle of minimal drawdowns during trends, with only a small fraction of the selected stocks experiencing significant pullbacks [5]. - The average drawdown for potential bull stocks in 2025 is lower than in previous years, theoretically making it easier to hold positions [5]. - The emergence of the volume accumulation model presents both challenges and opportunities for investors, suggesting a need for diversification in investment strategies [5].

Summary of Key Points from the Conference Call Industry Overview - The focus is on the non-pharmaceutical sector within the healthcare industry for the investment strategy in 2026, emphasizing overseas expansion and innovation as key growth drivers [2][12]. Key Companies and Sectors Insulin Sector - Core companies include Ganli Pharmaceutical, Federal Pharmaceutical, and Tonghua Dongbao, with Ganli's insulin products expected to receive European regulatory approval in 2026 [1][4]. - Ganli is expanding into European, American, and Asian markets, while Tonghua Dongbao is advancing its U.S. market strategy through Jiangyang [1][4]. Biopharmaceuticals - Blood products companies like Jinbao and Renbai are anticipated to see performance inflection points in the second half of 2026, with a focus on plasma station planning and state-owned enterprise reform opportunities [5]. - Vaccine companies such as Olin Bio, Kanghua Bio, and CanSino are highlighted, with Olin focusing on superbug vaccines and Kanghua developing RSV vaccines [5]. Traditional Chinese Medicine (TCM) - Investment opportunities in TCM include transformation and innovation (companies like Jiuzhitang, Yiling Pharmaceutical), essential drug catalog considerations, and OTC (over-the-counter) products [6][8]. - Key strategies involve dividend safety margins, valuation speculation post-policy implementation, and monitoring performance impacts from policy changes [8]. Medical Devices - The medical device sector is seeing significant overseas revenue contributions, with companies like Blueway, Mindray, and Kaili reporting 45%-60% of their income from international markets [9]. - Innovations in surgical robotics and brain-computer interfaces are critical areas of focus, with the latter having established a commercial closed loop [9]. Market Dynamics and Trends - The non-pharmaceutical sector is expected to benefit from changes in consumer behavior, particularly in internet healthcare, which has shown substantial growth potential compared to traditional retail [10][11]. - The shift in consumption patterns is creating new incremental opportunities across various segments, including pharmacies, medical services, and consumer healthcare [11]. Investment Strategy - The overarching strategy for 2026 emphasizes overseas expansion and innovation across insulin, medical devices, and TCM to achieve dual enhancements in valuation and performance [2][12]. - Investors are advised to closely monitor policy developments and market changes to identify quality investment opportunities in these sub-sectors [7][12].